Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Exclusion Criteria

• • Symptomatic central nervous system metastasis or any history of leptomeningeal disease or cord compression
• • A participant with an already known sensitising mutation or tumour characteristic for pancreatic cancer for which there is a preferred local standard-of-care treatment
• • History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention
• • Any unresolved toxicities ≥ Grade 2 per Common Terminology Criteria for Adverse Events v5.0 from prior therapy (excluding vitiligo, alopecia, controlled diabetes)
• • History of solid organ transplantation
• • History of active primary immunodeficiency
• • Ongoing or an active infection, including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus. A negative COVID-19 PCR test taken within 28 days of the start of the study treatment is required.
• • Uncontrolled intercurrent illness
• • Participants with prior history of myocardial infarction, transient ischemic attack, coronary bypass, or stroke within the past 3 months prior to the first dose of study intervention
• • Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 electrocardiograms
• • Active or prior documented autoimmune or inflammatory disorders
• • History of another primary malignancy
• • Receipt of any conventional or investigational anticancer therapy prior to the scheduled first dose of study intervention
• • Prior receipt of any immune-mediated therapy
• • Use of immunosuppressive medication within 14 days prior to the first dose of study intervention
• • Receipt of live, attenuated vaccine within 28 days prior to the first dose of study intervention (Participants can receive non-live COVID-19 vaccines, at the discretion of the Investigator)